Institut De Cancerologie De L Ouest

The Institut De Cancerologie De L Ouest in Saint-Herblain is conducting clinical research in cancer care with a focus on improving treatment options and long-term disease control. The studies center on neoplasms and explore both ongoing treatment safety and new approaches to prevent recurrence.

• Research on cancer treatment continuation and darolutamide safety
• Studies in ER+/HER2- early breast cancer aimed at reducing recurrence risk
• Evaluation of new endocrine-based therapies compared with standard care

These trials reflect a strong interest in medical oncology, especially therapies designed to support patients already receiving treatment and to improve outcomes in early-stage breast cancer.

At the Service d'Oncologie médicale, one key area of work is ER+/HER2- early breast cancer, where researchers are studying ways to prevent the disease from returning after initial treatment. The goal is to assess whether newer endocrine-based strategies can offer better protection than standard therapy.

• Prevention of breast cancer recurrence
• Testing camizestrant in combination with established treatment approaches
• Comparing new and standard endocrine therapy options

This line of research may help refine treatment choices for patients with hormone receptor-positive breast cancer and improve confidence in adjuvant care decisions.

Another important theme at this site is the follow-up of patients who have already received darolutamide in another study. The research focuses on maintaining treatment continuity while gathering additional information on safety and tolerability in real-world clinical use.

• Continuation of darolutamide treatment
• Monitoring treatment safety over time
• Supporting ongoing care for patients enrolled in prior studies

These efforts highlight the site's role in oncology research that supports both patient follow-up and the practical use of cancer therapies.